Apellis Pharmaceuticals Acquired by Biogen | Healthcare M&A Deal

Biogen has completed the acquisition of Apellis Pharmaceuticals, a pharmaceuticals business in Massachusetts, for $205,000,000. Biogen acquisitions focus on expanding healthcare M&A capabilities, while Apellis Pharmaceuticals develops therapies for patients through pharmaceutical R&D in MA. The merger acquisition structure uses a tender offer to acquire all outstanding Apellis common stock, supporting strategic acquisition goals for Biogen. Biogen, a strategic buyer, is executing this healthcare deals MA merger acquisition as part of a strategic acquisition, with an upfront cash price of $41.00 per share and expected completion following customary tender offer conditions.